CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 10 enrolled
Drug / intervention
Raptivadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00226057
NCT00226057Phase 1Completed
CompareCT.gov

Efalizumab for Moderate to Severe Atopic Dermatitis - A Phase I Pilot Study in Adults

Oregon Health and Science University·interventional·Posted Sep 26, 2005·Updated Jan 3, 2020

In Brief

A Phase 1 clinical trial evaluating Raptiva for Dermatitis, Atopic. Completed, enrolled 10 participants.

Detailed Summary

The purpose of this study is to determine if Raptiva will have beneficial effects in the treatment of patients with moderate to severe atopic dermatitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 26, 2005
Enrollment StartJun 1, 2005
Primary CompletionNov 1, 2005
Study CompletionMay 1, 2006
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 20.8 years ago

Interventions

Raptivadrug

Open Label